# Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer

> **NCT00002919** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** cisplatin
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** methotrexate
- **DRUG:** vinblastine sulfate
- **PROCEDURE:** conventional surgery

## Key facts

- **NCT ID:** NCT00002919
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-11
- **Primary completion:** 2003-01
- **Final completion:** 2003-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2013-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002919, "Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*